8329 — Shenzhen Neptunus Interlong Bio-technique Co Income Statement
0.000.00%
- HK$327.21m
- HK$234.21m
- CNY1.04bn
- 44
- 78
- 85
- 82
Annual income statement for Shenzhen Neptunus Interlong Bio-technique Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,031 | 839 | 987 | 1,065 | 1,042 |
Cost of Revenue | |||||
Gross Profit | 576 | 368 | 444 | 439 | 328 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 980 | 795 | 897 | 1,029 | 1,007 |
Operating Profit | 51 | 43.7 | 89.3 | 36.2 | 34.7 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 50.2 | 39.1 | 82.3 | 30.7 | 29.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 38.7 | 34.3 | 63.8 | 14.5 | 13.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 36.6 | 36 | 54.3 | 24.1 | 25 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 36.6 | 36 | 54.3 | 24.1 | 25 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.032 | 0.021 | 0.034 | 0.019 | 0.016 |
Dividends per Share | |||||
Special Dividends per Share |